Session

Prostate cancer screening and early detection

Poster Session 08

  • Location:
    Room Stockholm (Hall B2, level 0)
  • Chairs:
     S.V. Carlsson, New York (US)
     F.K-H. Chun, Hamburg (DE)
     O. Yossepowitch, Petah-Tikva (IL)
  • Aims and objectives of this session

    The session is focused on prostate cancer screening and early detection.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 86
The STHLM3 model improves prostate cancer testing in men 50-69 years - further health economic and clinic evaluation

By: Grönberg H.1, Adolfsson J.2, Aly M.1, Nordström T.1, Wiklund P.3, Brandberg Y.4, Thompson J.5, Wiklund F.1, Lindberg J.1, Clements M.1, Egevad L.4, Eklund M.1

Institutes: 1Karolinska Institutet, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, 2Karolinska Institutet, Dept. of Clinical Science, Intervention and Technology (CLINTEC), Stockholm, Sweden, 3Karolinska Institutet, Dept. of Molecular Medicine and Surgery, Stockholm, Sweden, 4Karolinska Institutet, Dept. of Oncology-Pathology, Stockholm, Sweden, 5Karolinska Institutet, Biobank, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden

* 87
18-year follow up of the Gothenburg randomized population-based prostate cancer screening trial

By: Arnsrud Godtman R.1, Carlsson S.1, Grenabo Bergdahl A.1, Holmberg E.2, Stranne J.1, Lilja H.3, Hugosson J.1

Institutes: 1Institute of Clinical Sciences, Sahlgrenska Academy at The University of Gothenburg, Dept. of Urology, Gothenburg, Sweden, 2Institute of Clinical Sciences, Sahlgrenska Academy at The University of Gothenburg, Dept. of Oncology, Gothenburg, Sweden, 3Memorial Sloan-Kettering Cancer Center/Nuffield Dept. of Surgical Sciences/Lund University Hospital, Dept. of Laboratory Medicine, Surgery (Urology), and Medicine (GU Oncology), Malmö, Sweden

88
Correlation between stage shift and differences in mortality between the two study arms of the ERSPC

By: Roobol M.J.1, Auvinen A.2, Carlsson S.V.3, Kwiatkowski M.4, Denis L.J.5, Zappa M.6, Paez A.7, Hugosson J.8, Moss S.M.9, Bokhorst L.P.1

Institutes: 1Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, 2University of Tampere, School of Medicine, Tampere, Finland, 3Sahlgrenska Academy At University of Gothenburg/Memorial Sloan-Kettering Cancer Center, Dept. of Urology, Gothenburg, Sweden, 4Kantonsspital Aarau, Dept. of Urology, Aaurau, Switzerland, 5Europa Uomo, Antwerp, Belgium, 6ISPO, Unit of Clinical and Descriptive Epidemiology, Florence, Italy, 7Hospital Universitario De Fuenlabrada, Dept. of Urology, Madrid, Spain, 8Sahlgrenska Academy At University of Gothenburg, Dept. of Urology, Gothenburg, Sweden, 9Centre For Cancer Prevention, Queen Mary University of London, Cancer Prevention, London, United Kingdom

89
The association between family history and prostate-specific antigen from a large group of 45-year old men embarking on prostate cancer screening: Results from the PROBASE trial

By: Herkommer K.1, Laenger N.1, Klorek T.1, Ankerst D.2, Grill S.2, Schulwitz H.1, Albers P.3, Arsov C.3, Hadaschik B.4, Hohenfellner M.4, Kuczyk M.5, Imkamp F.5, Gschwend J.1

Institutes: 1Technical University of Munich, Dept. of Urology, Munich, Germany, 2Technical University of Munich, Dept. of Mathematics, Munich, Germany, 3University Dusseldorf, Medical Faculty, Dept. of Urology, Dusseldorf, Germany, 4University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 5Hanover Medical School, Dept. of Urology, Hanover, Germany

90
Differences in prostate specific antigen testing among urologists and primary care providers in the United States following the 2011 USPSTF recommendations

By: Meyer C.1, Zavaski M.1, Hanske J.1, Friedlander D.1, Cheng P.1, Menon M.2, Kibel A.1, Cole A.1, Leow J.1, Abdollah F.2, Sun M.1, Sammon J.2, Trinh Q-D.1

Institutes: 1Brigham and Women’s Hospital, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, 2Henry Ford Hospital, Vatikutti Urology Institute, Detroit, United States of America

91
The impact of 2012 United States Preventive Services Task Force (USPSTF) panel update on PSA screening practice: A nationwide, and state-by-state level analyses

By: Abdollah F.F.H.1, Dalela D.1, Sood A.1, Meyer C.2, Sun M.2, Trinh Q.D.2, Menon M.1, Sammon J.1

Institutes: 1Henry Ford Hospital / Health System, Dept. of Urology, Detroit, United States of America, 2Brigham and Women’s Hospital / Dana-Farber Cancer Institute, Harvard Medical School, Dept. of Urologic Surgery and Center for Surgery and Public Health, Detroit, United States of America

92
Swiss prostate-check: A population based risk-calculator for next generation prostate cancer screening

By: Kwiatkowski M.1, Wyler S.F.1, Prause L.1, Möltgen T.1, Huber A.2, Grobholz R.3, Manka L.4, Seifert B.5, Randazzo M.6, Recker F.1

Institutes: 1Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland, 2Cantonal Hospital Aarau, Dept. of Laboratory Medicine, Aarau, Switzerland, 3Cantonal Hospital Aarau, Dept. of Pathology, Aarau, Switzerland, 4Academic Hospital Braunschweig, Dept. of Urology, Braunschweig, Germany, 5University of Zurich, Institute for Biostatistics, Zürich, Switzerland, 6University of Zurich, Dept. of Urology, Zürich, Switzerland

93
A nationwide survey of prostate specific antigen based screening and counseling for prostate cancer

By: Meyer C.1, Friedlander D.1, Choi K.1, Cole A.1, Abdollah F.2, Hanske J.1, Zavaski M.1, Sammon J.3, Leow J.1, Menon M.3, Sun M.1, Kibel A.1, Trinh Q-D.1

Institutes: 1Brigham and Women’s Hospital, Dept. of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, 2Henry Ford Hospital, Dept. of Urology, Detroit, United States of America, 3Henry Ford Hospital, Vatikutti Urology Institute, Detroit, United States of America

94
Informed decision-making for prostate-specific antigen screening

By: Hanna N.1, Zavaski M.1, Gelpi-Hammerchmidt F.1, Meyer C.1, Sammon J.2, Kibel A.1, Menon M.2, Leow J.1, Sun M.1, Abdollah F.2, Trinh Q-D.1

Institutes: 1Brigham and Women’s Hospital, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, 2Henry Ford Hospital, Vatikutti Urology Institute, Detroit, United States of America

95
Detection of asymptomatic locally advanced and high-risk prostate cancer through PSA testing: Clinical outcomes in men excluded from the ProtecT Trial

By: Johnston T.1, Shaw G.1, Lamb A.2, Gnanapragasam V.1, Greenberg D.3, Parashar D.4, Xiong T.1, Moore A.1, Holding P.5, Herbert P.1, Davis M.6, Down E.6, Lane J.A.6, Donovan J.6, Hamdy F.7, Neal D.1

Institutes: 1Cambridge University and Cambridge University Hospitals NHS Trust, Surgical Academic Urological Grou, Dept. of Surgery, Cambridge, United Kingdom, 2Cambridge University and Cambridge University Hospitals NHS Trust, Cambridge, Uk, Dept. of Urology, Cambridge, United Kingdom, 3National Cancer Registration Service – Eastern Office, Dept. of Public Health, Cambridge, United Kingdom, 4Cancer Research UK Cambridge Institute, Dept. of Urology, Cambridge, United Kingdom, 5Academic Urology Unit, Royal Hallamshire Hospital,, Dept. of Surgery, Sheffield, United Kingdom, 6School of Social and Community Medicine, Dept. of Urology, Bristol, United Kingdom, 7Nuffield Department of Surgical Sciences, Dept. of Surgery, Oxford, United Kingdom

96
Comorbidities and concomitant medications at time of diagnosis of prostate cancer: Data from the PROS-IT CNR study

By: Gacci M.1, Artibani W.2, Bassi P.3, Bertoni F.4, Bracarda S.5, Conti G.6, Corvò R.7, Graziotti P.8, Maggi S.9, Magrini S.M.10, Maurizi Enrici R.11, Mirone V.12, Montironi R.13, Muto G.14, Noale M.9, Pecoraro S.15, Porreca A.16, Ricardi U.17, Tubaro A.18, Zagonel V.19, Zattoni F.20

Institutes: 1University of Florence, Dept. of Urology, Florence, Italy, 2Azienda Ospedaliera Universitaria Integrata and University of Verona, Dept. of Urology and Oncological and Surgical Sciences, Verona, Italy, 3University of Rome La Cattolica, Dept. of Urology, Rome, Italy, 4Italian Association For Radiation Oncology, Referent For The Prostate Group of AIRO, Rome, Italy, 5Ospedale San Donato, Azienda USL8, Dept. of Medical Oncology, Arezzo, Italy, 6St. Anna Hospital, Dept. of Urology, Como, Italy, 7AOU IRCCS San Martino – IST National Cancer Research Institute and University, Dept. of Radiation Oncology, Genoa, Italy, 8Ospedale S. Giuseppe, Dept. of Urology, Milan, Italy, 9CNR, Neuroscience Institute, Dept. of Aging Branch, Padua, Italy, 10University of Brescia and Spedali Civili Hospital, Dept. of Radiation Oncology Unit, Brescia, Italy, 11University “La Sapienza”, Dept. of Radiation Oncology, Rome, Italy, 12University Federico II, Dept. of Urology, Naples, Italy, 13Polytechnic University of The Marche Region, Section of Pathological Anatomy, Ancona, Italy, 14Campus Bio-Medico University of Rome, Dept. of Urology, Rome, Italy, 15Malzoni Center, Dept. of Nephrourology, Avellino, Italy, 16Abano Terme General Hospital, Dept. of Urology, Padua, Italy, 17University of Turin, Dept. of Oncology, Radiation Oncology, Turin, Italy, 18Sant’Andrea Hospital, Sapienza University of Rome, Dept. of Urology, Rome, Italy, 19Istituto Oncologico Veneto IOV – IRCCS, Dept. of Medical Oncology, Padua, Italy, 20University of Padua, Dept. of Urology , Padua, Italy

97
Repeat prostate-specific antigen (PSA) tests before biopsy decisions: Results from the STHLM3 diagnostic trial

By: Nordström T.1, Adolfsson J.2, Grönberg H.1, Eklund M.1

Institutes: 1Karolinska Institute, Dept. of Medical Epidemiology and Biostatistics, Stockholm, Sweden, 2Karolinska Institute, Dept. of Clinical Science, Intervention and Technology, Stockholm, Sweden

Summary and context
 S.V. Carlsson, New York (US)